Trends in the prescribing of psychotropic medications to preschoolers.

CONTEXT Recent reports on the use of psychotropic medications for preschool-aged children with behavioral and emotional disorders warrant further examination of trends in the type and extent of drug therapy and sociodemographic correlates. OBJECTIVES To determine the prevalence of psychotropic medication use in preschool-aged youths and to show utilization trends across a 5-year span. DESIGN Ambulatory care prescription records from 2 state Medicaid programs and a salaried group-model health maintenance organization (HMO) were used to perform a population-based analysis of three 1-year cross-sectional data sets (for the years 1991, 1993, and 1995). SETTING AND PARTICIPANTS From 1991 to 1995, the number of enrollees aged 2 through 4 years in a Midwestern state Medicaid (MWM) program ranged from 146,369 to 158,060; in a mid-Atlantic state Medicaid (MAM) program, from 34,842 to 54,237; and in an HMO setting in the Northwest, from 19,107 to 19,322. MAIN OUTCOME MEASURES Total, age-specific, and gender-specific utilization prevalences per 1000 enrollees for 3 major psychotropic drug classes (stimulants, antidepressants, and neuroleptics) and 2 leading psychotherapeutic medications (methylphenidate and clonidine); rates of increased use of these drugs from 1991 to 1995, compared across the 3 sites. RESULTS The 1995 rank order of total prevalence in preschoolers (per 1000) in the MWM program was: stimulants (12.3), 90% of which represents methylphenidate (11.1); antidepressants (3.2); clonidine (2.3); and neuroleptics (0.9). A similar rank order was observed for the MAM program, while the HMO had nearly 3 times more clonidine than antidepressant use (1.9 vs 0.7). Sizable increases in prevalence were noted between 1991 and 1995 across the 3 sites for clonidine, stimulants, and antidepressants, while neuroleptic use increased only slightly. Methylphenidate prevalence in 2- through 4-year-olds increased at each site: MWM, 3-fold; MAM, 1.7-fold; and HMO, 3.1-fold. Decreases occurred in the relative proportions of previously dominant psychotherapeutic agents in the stimulant and antidepressant classes, while increases occurred for newer, less established agents. CONCLUSIONS In all 3 data sources, psychotropic medications prescribed for preschoolers increased dramatically between 1991 and 1995. The predominance of medications with off-label (unlabeled) indications calls for prospective community-based, multidimensional outcome studies.

[1]  M. Riddle,et al.  Critical review of tricyclic antidepressant use in children and adolescents. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[2]  J. Swanson,et al.  Combining methylphenidate and clonidine: a clinically sound medication option. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[3]  S. Gortmaker,et al.  Changing patterns of conditions among children receiving Supplemental Security Income disability benefits. , 1999, Archives of Pediatrics & Adolescent Medicine.

[4]  C. Kappagoda,et al.  Clonidine overdose in childhood: Implications of increased prescribing , 1998, Journal of paediatrics and child health.

[5]  M. Rappley,et al.  Diagnosis of ADHD and Treatment with Psychotropic Medications in Children Ages 1 To 3 Years , 1998 .

[6]  L. Greenhill The Use of Psychotropic Medication in Preschoolers: Indications, Safety, and Efficacy , 1998, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[7]  B. Vitiello Pediatric Psychopharmacology and the Interaction between Drugs and the Developing Brain , 1998, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[8]  K. Minde The Use of Psychotropic Medication in Preschoolers: Some Recent Developments , 1998, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[9]  A. Duncan,et al.  Clonidine poisoning—an emerging problem: Epidemiology, clinical features, management and preventative strategies , 1998, Journal of paediatrics and child health.

[10]  D A Zarin,et al.  Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. , 1998, JAMA.

[11]  S. Speedie,et al.  Prevalence variations in psychotropic treatment of children. , 1998, Journal of child and adolescent psychopharmacology.

[12]  S. Bennett,et al.  Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. , 1998, Journal of child and adolescent psychopharmacology.

[13]  C. Arpino,et al.  Prescription of neuroleptics for children and adolescents in Italy. , 1998, Journal of child and adolescent psychopharmacology.

[14]  P. Jensen,et al.  Medication development and testing in children and adolescents. Current problems, future directions. , 1997, Archives of general psychiatry.

[15]  J. Swanson,et al.  Case study: adverse response to clonidine. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[16]  D. Safer,et al.  Increased methylphenidate usage for attention deficit disorder in the 1990s. , 1996, Pediatrics.

[17]  B J Burns,et al.  Outcomes of mental health care for children and adolescents: I. A comprehensive conceptual model. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[18]  S. Zubrick,et al.  National trends in the use of stimulant medication for attention deficit hyperactivity disorder , 1996, Journal of paediatrics and child health.

[19]  J. Biederman,et al.  Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[20]  C. Popper Combining Methylphenidate and Clonidine: Pharmacologic Questions and News Reports about Sudden Death , 1995 .

[21]  J. Swanson,et al.  Clonidine in the Treatment of ADHD: Questions about Safety and Efficacy , 1995 .

[22]  P. Jensen,et al.  Design and methodology issues for clinical treatment trials in children and adolescents. Child and adolescent psychopharmacology: expanding the research base. , 1994, Psychopharmacology bulletin.

[23]  P. Ahmann,et al.  Placebo-controlled evaluation of Ritalin side effects. , 1993, Pediatrics.

[24]  R. Brook,et al.  Childhood enuresis: prevalence, perceived impact, and prescribed treatments. , 1986, Pediatrics.